STOCK TITAN

Charles River Laboratories International (CRL) DEF 14A Filings

CRL NYSE

Here are the DEF 14A proxy statements from Charles River Laboratories International, Inc. (CRL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CRL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRL filings page.

Rhea-AI Summary

Charles River Laboratories International, Inc. is asking shareholders to vote at its May 5, 2026 annual meeting on four main items: electing twelve directors, approving a new long-term incentive plan, holding an advisory vote on executive pay, and ratifying PricewaterhouseCoopers LLP as auditor for 2026.

The proxy highlights a leadership transition in which long-time Chair and CEO James C. Foster will retire from those roles, with Chief Operating Officer Birgit Girshick becoming Chief Executive Officer and joining the Board, while Foster remains a non-executive director. The company seeks approval of a 2026 Long-Term Incentive Plan authorizing up to 4,825,000 shares of common stock for equity awards to support its compensation and retention strategy. It also notes strong prior say-on-pay support and describes governance features such as majority voting, proxy access, board evaluations, independent committees, and a clawback policy.